Grace Therapeutics, Inc.
GRCE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $47,455 | $47,296 | $31,277 | $43,032 |
| - Cash | $16,862 | $20,005 | $22,133 | $11,055 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $30,593 | $27,291 | $9,144 | $31,977 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | -$2 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$938 | -$3,088 | -$380 | -$3,702 |
| % Margin | – | – | – | – |
| Net Income | -$938 | -$3,362 | $636 | -$4,155 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.06 | -0.21 | 0.046 | -0.36 |
| % Growth | 71.4% | -552.6% | 112.9% | – |
| Operating Cash Flow | -$3,155 | -$1,801 | -$2,954 | -$4,115 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$3,155 | -$1,801 | -$2,954 | -$4,115 |